After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Mereo Biopharma Group Plc ADR is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Mereo Biopharma Group Plc ADR is $385.28M. A total of 1.77 million shares were traded on the day, compared to an average of 1.17M shares.
In the most recent transaction, Scots-Knight Denise sold 60,046 shares of MREO for 4.22 per share on Sep 13 ’24. After the transaction, the Chief Executive Officer now owns 808,921 company shares. In a previous transaction on Sep 12 ’24, Scots-Knight Denise sold 28,611 shares at 4.47 per share. MREO shares that Chief Executive Officer owns now total 868,967.
Among the insiders who sold shares, Lewicki John A. disposed of 10,937 shares on Sep 13 ’24 at a per-share price of $4.22. This resulted in the Chief Scientific Officer holding 78,630 shares of MREO after the transaction. In another insider transaction, Lewicki John A. sold 5,212 shares at $4.47 per share on Sep 12 ’24. Company shares held by the Chief Scientific Officer now total 89,567.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for MREO in the last 3 months, the mean price target is $7.34 with high estimates of $10.00 and low estimates of $5.70. In terms of 52-week highs and lows, MREO has a high of $5.02 and a low of $2.32.
As of this writing, MREO has an earnings estimate of -$0.01 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.01 per share and a lower estimate of -$0.02.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. MREO’s latest balance sheet shows that the firm has $127.27M in Cash & Short Term Investments as of fiscal 2021. There were $22.62M in debt and $16.93M in liabilities at the time. Its Book Value Per Share was $0.47, while its Total Shareholder’s Equity was $118.77M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MREO is Buy with a score of 4.86.
